Cardiovascular disease is the leading cause of death and hospitalization in the world. In Canada 80,000 people died in 2010 of cardiovascular disease, which accounts for 35 per cent of all deaths in the country. Currently, 1.3 million Canadians suffer from cardiovascular disease, causing a serious economic burden. The cost is estimated to $22.2 billion per year, which constitutes the highest direct healthcare costs.
The team led by Drs. JeanClaude Tardif and MariePierre Dubé are applying their expertise in how genes influence drug efficacy and toxicity to provide guidance to health professionals in the selection and dosing of a specific drug. This will improve patient care, reduce harmful side effects and lower health care costs by reducing the use of ineffective drugs and unnecessary spending by healthcare payers.